86 related articles for article (PubMed ID: 18261722)
1. Regulation of intracellular dopamine levels by dopaminergic drugs: involvement of vesicular monoamine transporter.
Izumi Y; Yamamoto N; Kume T; Katsuki H; Sawada H; Akaike A
Eur J Pharmacol; 2008 Mar; 582(1-3):52-61. PubMed ID: 18261722
[TBL] [Abstract][Full Text] [Related]
2. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells.
Kantor L; Hewlett GH; Park YH; Richardson-Burns SM; Mellon MJ; Gnegy ME
J Pharmacol Exp Ther; 2001 Jun; 297(3):1016-24. PubMed ID: 11356924
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
Truong JG; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
[TBL] [Abstract][Full Text] [Related]
6. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
Oda T; Kume T; Izumi Y; Takada-Takatori Y; Niidome T; Akaike A
Eur J Pharmacol; 2008 Nov; 598(1-3):27-31. PubMed ID: 18835264
[TBL] [Abstract][Full Text] [Related]
7. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response.
Iravani MM; Sadeghian M; Leung CC; Tel BC; Rose S; Schapira AH; Jenner P
Exp Neurol; 2008 Aug; 212(2):522-31. PubMed ID: 18571649
[TBL] [Abstract][Full Text] [Related]
8. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
[TBL] [Abstract][Full Text] [Related]
9. Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism.
Sai Y; Wu Q; Le W; Ye F; Li Y; Dong Z
Toxicol In Vitro; 2008 Sep; 22(6):1461-8. PubMed ID: 18579341
[TBL] [Abstract][Full Text] [Related]
10. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.
Vergo S; Johansen JL; Leist M; Lotharius J
Brain Res; 2007 Dec; 1185():18-32. PubMed ID: 18028884
[TBL] [Abstract][Full Text] [Related]
11. Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure.
Hondebrink L; Meulenbelt J; Timmerman JG; van den Berg M; Westerink RH
J Neurochem; 2009 Oct; 111(2):624-33. PubMed ID: 19702656
[TBL] [Abstract][Full Text] [Related]
12. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
[TBL] [Abstract][Full Text] [Related]
13. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurochem; 2007 May; 101(4):883-8. PubMed ID: 17250674
[TBL] [Abstract][Full Text] [Related]
14. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex.
Charbit AR; Akerman S; Goadsby PJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):752-63. PubMed ID: 19657051
[TBL] [Abstract][Full Text] [Related]
16. Both mild hypothermia and dopamine D(2) agonist are neuroprotective against hyperthermia-induced injury in PC12 cells.
Cheng BC; Chang CP; Liu WP; Lin MT
Neurosci Lett; 2008 Oct; 443(3):140-4. PubMed ID: 18692549
[TBL] [Abstract][Full Text] [Related]
17. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist.
Okura T; Ito R; Ishiguro N; Tamai I; Deguchi Y
Life Sci; 2007 Apr; 80(17):1564-71. PubMed ID: 17307202
[TBL] [Abstract][Full Text] [Related]
18. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
19. Chlorpyrifos exposure causes alternation in dopamine metabolism in PC12 cells.
Xu F; Chang X; Lou D; Wu Q; Zhou Z
Toxicol Mech Methods; 2012 May; 22(4):309-14. PubMed ID: 22356570
[TBL] [Abstract][Full Text] [Related]
20. The role of dopamine transporter in selective toxicity of manganese and rotenone.
Hirata Y; Suzuno H; Tsuruta T; Oh-hashi K; Kiuchi K
Toxicology; 2008 Feb; 244(2-3):249-56. PubMed ID: 18206288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
